Expert Interview
A Second Look at PDS Bio's PDS101 immunotherapy in HPV16+ Cancers
Ticker(s): PDSBInstitution: MD Anderson
- Professor of Medicine Thoracic-Head & Neck Med Oncology at The University of Texas MD Anderson Cancer Center.
- Manages 20 patients with HNSCC per week.
- Research focused on defining the biological and molecular effects of the modulation of signal transduction pathways in lung, head and neck, and HPV+ cancers; has defined novel mechanisms of sensitivity and resistance to kinase inhibitors.
Roughly how many patients do you treat with HNSCC?
Added By: michael_adminHow would you rate your level of excitement for this agent (10 being extremely excited)?
Added By: michael_adminHow important do you think the other agents in the triple combination are (The IL-12 PDS0301 and Bintrafusp Alfa) to achieving good clinical outcomes?
Added By: michael_adminWhat other agents in development for HNSCC are you most excited about? Do you think these could be competitive to PDS0101 or complimentary?
Added By: michael_adminRecently MD Anderson presented early results of PDS0101 in combination with chemotherapy in cervical cancer, showing elimination or circulating tumor DNA and t-cell infiltration into the tumor. How important are these biomarkers? Are there important markers that you would like to see in HNSCC that would be predictive of efficacy?
Added By: michael_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
